Cryofocus Medtech (Shanghai) Co., Ltd. Stock

Equities

6922

CNE100005MV5

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:12 2024-07-19 EDT 5-day change 1st Jan Change
8.05 HKD -0.12% Intraday chart for Cryofocus Medtech (Shanghai) Co., Ltd. +0.75% -57.23%

Financials

Sales 2024 * 171M 23.59M 184M 32.39M Sales 2025 * 351M 48.22M 377M 66.2M Capitalization 1.79B 246M 1.92B 338M
Net income 2024 * -67M -9.22M -71.99M -12.65M Net income 2025 * -15M -2.06M -16.12M -2.83M EV / Sales 2024 * 10.4 x
Net cash position 2024 * - 0 0 0 Net cash position 2025 * - 0 0 0 EV / Sales 2025 * 5.11 x
P/E ratio 2024 *
-26.3 x
P/E ratio 2025 *
-125 x
Employees 392
Yield 2024 *
-
Yield 2025 *
-
Free-Float 15.24%
More Fundamentals * Estimated data
Dynamic Chart
1 day-0.12%
1 week+0.75%
Current month+7.33%
1 month+4.27%
3 months-19.01%
6 months-26.82%
Current year-57.23%
More quotes
1 week
8.05
Extreme 8.05
8.20
1 month
7.54
Extreme 7.54
8.20
Current year
5.00
Extreme 5
18.82
1 year
5.00
Extreme 5
19.50
3 years
5.00
Extreme 5
19.50
5 years
5.00
Extreme 5
19.50
10 years
5.00
Extreme 5
19.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 19-04-30
Chairman 34 21-05-31
Director of Finance/CFO 34 20-09-30
Members of the board TitleAgeSince
Director/Board Member 69 21-12-01
Director/Board Member 55 14-06-30
Chief Executive Officer 50 19-04-30
More insiders
Date Price Change Volume
24-07-19 8.05 -0.12% 12,200
24-07-18 8.06 -0.37% 12,000
24-07-17 8.09 -0.61% 10,800
24-07-16 8.14 -0.37% 11,800
24-07-15 8.17 +2.25% 11,200

Delayed Quote Hong Kong S.E., July 19, 2024 at 04:08 am

More quotes
Cryofocus Medtech Shanghai Co Ltd is a China-based medical device company, focusing on the research, development and commercialization of cryotherapy devices. The Company has built a comprehensive product portfolio comprising two core products, approximately 15 other product candidates in various development stages as well as approximately six additional commercialized medical consumables. The two core products comprise the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Company's products mainly target two therapeutic areas: natural orifice transluminal endoscopic surgery, to treat urinary, respiratory, and digestive diseases (such as bladder cancer, COPD, asthma, airway stenosis, gastric cancer, esophageal cancer and others), and vascular interventional therapy to treat cardiovascular diseases (such as atrial fibrillation, hypertension and others).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.493 CNY
Average target price
25.57 CNY
Spread / Average Target
+241.30%
Consensus

Annual profits - Rate of surprise